Recently it was reported that inhibition of TSLP using tezepelumab increases the efficacy of subcutaneous allergen immunotherapy in patients with allergic rhinitis to cats and may promote tolerance after a one-year course of treatment [81]. The gene discussed is TSLP; the disease is allergic rhinitis.